<scp>HBV</scp>/<scp>HIV</scp> coinfection is associated with poorer outcomes in hospitalized patients with <scp>HBV</scp> or <scp>HIV</scp>

Rajbhandari, Ruma; Jun, Tomi; Khalili, Hamed; Chung, Raymond T.; Ananthakrishnan, Ashwin N.

doi:10.1111/jvh.12555

Cited by 40 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion of tenofovir for management of HBV has led to significant improvements in HBV viral control and liver fibrosis and decreased HBV drug resistance [64, 91–94] . However, recent studies continue to report that overall mortality, liver related mortality and hospital utilization rates and risk of hepatocellular carcinoma (HCC) remain elevated in HIV-HBV co-infected individuals compared to HIV mono- or HBV mono-infected individuals [2, 3, 5, 6, 8, 70, 95–99] . Furthermore, liver disease progression continues to occur in 10–20% of individuals on tenofovir-containing HBV-active ART [5, 100, 101] (summarized in Table 1).…”

Section: Natural History Of Hiv-hbv Co-infection In the Era Of Hbvmentioning

confidence: 99%

HIV-hepatitis B virus coinfection

Singh¹,

Crane

Audsley

et al. 2017

Aids

191

View full text Add to dashboard Cite

HIV infection has a significant impact on the natural history of chronic HBV infection, with increased levels of HBV DNA, accelerated progression of liver disease and increased liver-associated mortality compared to HBV mono-infection. Widespread uptake and early initiation of HBV-active antiretroviral therapy (ART) has substantially improved the natural history of HIV-HBV co-infection but the prevalence of liver disease remains elevated in this population. In this paper, we review recent studies examining the natural history and pathogenesis of liver disease and seroconversion in HIV-HBV co-infection in the era of HBV-active ART and the effects of HIV directly on liver disease. We also review novel therapeutics for the management of HBV with a particular emphasis on clinical strategies being developed for an HBV cure and an HIV cure and their impact on HIV-HBV co-infected individuals.

show abstract

Section: Natural History Of Hiv-hbv Co-infection In the Era Of Hbvmentioning

confidence: 99%

HIV-hepatitis B virus coinfection

Singh¹,

Crane

Audsley

et al. 2017

Aids

191

View full text Add to dashboard Cite

show abstract

“…Incidence of hepatic fibrosis (14.2%) and cirrhosis (9.2%) is more likely to occur in HIV/HBV co-infection patients [28][29][30][31] and the liver-related mortality in these patients was 8 times higher than that in HIV monoinfection patients [2,32]. Besides, HIV/HBV coinfection is a risk factor for in-hospital mortality [33], which also heightened overall mortality rates (Incidence Rate Ratio: 1.24) [34][35][36][37].…”

Section: Introductionmentioning

confidence: 99%

The evaluation of antiretroviral treatment in HIV and hepatitis B virus (HBV) co-infected persons in Beijing, China, 2010-2018: a retrospective cohort study

Guo

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

There is limited long-term data on the effect of ART on clinical outcomes in HIV/HBV patients in China. The objective of this study was to understand the ART treatment effect and the factors associated with the loss to follow-up or death of HIV/HBV co-infected patients in the city of Beijing, China. Methods: This study examined clinical indicators for HIV mono-infected or HIV/HBV co-infected patients from Jan. 2010 to Sep. 2018. Included patients were followed for a mean duration of 34.5 months after ART. Covariance analysis for repeated measures was used to analyze the changes of clinical indicators; multivariate logistic regression and Cox model were used to analyze the influencing factors of the abnormal incidence of clinical indicators and the lost to follow-up or death in HIV patients. Results: A total of 841 HIV/HBV co-infected patients and 2000 HIV patients were analyzed. Adherence was estimated to be 93% in all patients. At baseline, ALT, AST, OIs and APRI≥0.5 in HIV/HBV patients were higher, while the CD4 and CD4/CD8 ratio were lower. After ART treatment, the rate of APRI≥0.5 (4.4%) were still higher in HIV/HBV patients and HBV co-infection affect the prevalence of APRI≥0.5 (OR=2.745, 95% CI 1.041-7.243). The variables related to LTFU or death in HIV patients were initial CD4 (HR=0.784, 95% CI 0.652-0.943), APRI≥0.5 (HR=4.647, 95% CI 1.331-16.227), OIs (HR=4.910, 95% CI 2.352-10.247) and age (HR=1.336, 95% CI 1.004-1.778). HBV coinfection was not associated with increased LTFU or overall mortality in HIV patients (p>0.05). Conclusion: With good ART treatment and adherence rate, the clinical indicators were improved significantly in HIV/HBV co-infected patients. However, the incidence of hepatic fibrosis was higher in these patients.

show abstract

“…Progression to cirrhosis was thought to occur gradually over 25 to 30 years; however, some data suggest that this progression can occur over 5 to 10 years in some individuals, especially in those over 58 years of age [7]. Other factors that accelerate progression to cirrhosis include coinfection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) [8,9]. Once cirrhosis develops, 25% of patients will develop hepatocellular carcinoma and/or decompensated liver disease, and eventually death [7].…”

Section: Introductionmentioning

confidence: 99%